Celecoxib And Docetaxe Inhibited Proliferation And Induced Apoptosis Of Breast Cancer Cell Line MDA-MB-231

ObjectiveTo observe the inhibitory effect of docetaxel combined with celecoxib onhuman breast cancer MDA-MB-231cells in vitro and study its effect on theexpression of bcl-2、bax and survivin. Elucidate its possible mechanism andprovide experimental basis for further clinical application.MethodsMDA-MB-231treated by various concentrations of celecoxib and docetaxelalone or in combination.1.MTT method was used to detect cell survival rate and the two druginteraction coefficients (CDI) to evaluate the two drug interaction properties,CDI=AB/A×B, where AB is the two drug combination group and control groupod ratio, A or B is the single drug group and control group OD ratio. CDI<1,show that the nature of two drugs for collaborative; CDI=1, is the nature of thetwo drugs is added; CDI>1, is the nature of the two drugs is antagonistic;2.Wright-Giemsa staining was used to observe morphological changes.3.Annexin V/PI flow cytometry was used to analyze cell apoptosis4.Western Blot method was used to detect the expression of bax、bcl-2and survivin. Results1.celecoxib or docetaxel effectively inhibited the growth of MDA-MB-231breast cancer cells in a concentration-dependent manner at certein range ofconcentrations.The cell viability rate of celecoxib combined with docetaxel wassignificantly lower than that of single drug group (P<0.05)，and CDI<1at48hwhen cells induced by combination group.2.Apoptosis bodies emerged when the cells were treated with60umol/Lcelecoxib combination with2.0umol/Ldocetaxel after48h.3.The apoptosis rate at48h induced by60umol/L celecoxib and2.0umol/Ldocetaxel was (20.14±1.217)%、(54.60±1.371)%respectively,and lower thanthat induced by combined treatment (59.89±1.415)%,(P<0.05).4.The results of Western Blot showed that after48h on cells,the expressionof bcl-2in celecoxib group，docetaxel group and combination group decreasedto89.02%、75.63%、45.35%of the control group respectively,and the differencewas statistically significant (X~2=13.77，P<0.05).the expression of bax increasedto136.35%、157.24%、173.89%of the control group and the difference wasstatistically significant （X~2=4.79，P＜0.05）.And the expression of survivindecreased to80.42%、54.28%、35.85%of the control group in the three groupsand the difference was statistically significant（X~2=10.28，P＜0.05）.Conclusioncelecoxib and docetaxel had a synergistic effect on growth inhibition andapoptosis breast cancer MDA-MB-231cells and decreased bcl-2、survivinexpression and enhanced bax expression.